FY2028 EPS Estimates for Precigen, Inc. (NASDAQ:PGEN) Lowered by Analyst

Precigen, Inc. (NASDAQ:PGEN - Free Report) - Research analysts at HC Wainwright cut their FY2028 earnings per share estimates for Precigen in a research report issued to clients and investors on Wednesday, May 15th. HC Wainwright analyst S. Ramakanth now expects that the biotechnology company will earn $0.62 per share for the year, down from their prior forecast of $0.63. HC Wainwright currently has a "Buy" rating and a $6.00 target price on the stock. The consensus estimate for Precigen's current full-year earnings is ($0.33) per share.

Other research analysts have also issued research reports about the company. JPMorgan Chase & Co. cut Precigen from a "neutral" rating to an "underweight" rating in a research report on Friday, March 22nd. Cantor Fitzgerald reiterated an "overweight" rating on shares of Precigen in a report on Wednesday. JMP Securities reissued a "market outperform" rating and set a $14.00 price target on shares of Precigen in a research report on Wednesday, March 20th. Stifel Nicolaus reaffirmed a "buy" rating and issued a $7.00 price objective on shares of Precigen in a research report on Wednesday. Finally, StockNews.com raised shares of Precigen to a "sell" rating in a research report on Tuesday, March 26th. Two research analysts have rated the stock with a sell rating and four have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $9.00.

Precigen Stock Down 2.8 %

PGEN stock traded down $0.04 during mid-day trading on Thursday, reaching $1.40. 761,242 shares of the company traded hands, compared to its average volume of 1,003,192. The firm's 50 day moving average price is $1.41 and its 200 day moving average price is $1.34. The stock has a market cap of $348.49 million, a price-to-earnings ratio of -3.59 and a beta of 1.77. Precigen has a fifty-two week low of $0.84 and a fifty-two week high of $1.88.

Precigen (NASDAQ:PGEN - Get Free Report) last released its quarterly earnings data on Tuesday, May 14th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.01). The business had revenue of $1.07 million during the quarter, compared to the consensus estimate of $1.54 million. Precigen had a negative net margin of 1,540.63% and a negative return on equity of 55.47%. During the same period last year, the business posted ($0.10) earnings per share.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PGEN. Fortis Group Advisors LLC purchased a new stake in shares of Precigen during the 1st quarter worth approximately $28,000. Fisher Asset Management LLC purchased a new stake in Precigen in the fourth quarter worth $29,000. EntryPoint Capital LLC purchased a new position in shares of Precigen during the 1st quarter valued at $31,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Precigen by 338.8% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 28,788 shares of the biotechnology company's stock worth $39,000 after acquiring an additional 22,227 shares during the period. Finally, Diversified Trust Co purchased a new stake in Precigen in the 4th quarter worth about $39,000. 33.51% of the stock is currently owned by hedge funds and other institutional investors.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.